Liabilities, Current of ArriVent BioPharma, Inc. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary: ArriVent BioPharma, Inc. quarterly Liabilities, Current in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
ArriVent BioPharma, Inc. Liabilities, Current for the quarter ending 31 Dec 2025 was $25,945,000, a 50% increase year-over-year.
Source SEC data: View on sec.gov

Liabilities, Current, Quarterly (USD)

Liabilities, Current, YoY Quarterly Change (%)

ArriVent BioPharma, Inc. Quarterly Liabilities, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$25,945,000	+$8,671,000	+50%	31 Dec 2025	10-K	05 Mar 2026	2025	FY
Q3 2025	$21,558,000	+$6,396,000	+42%	30 Sep 2025	10-Q	10 Nov 2025	2025	Q3
Q2 2025	$19,636,000	+$7,538,000	+62%	30 Jun 2025	10-Q	11 Aug 2025	2025	Q2
Q1 2025	$12,953,000	+$2,976,000	+30%	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$17,274,000	+$5,650,000	+49%	31 Dec 2024	10-K	05 Mar 2026	2025	FY
Q3 2024	$15,162,000			30 Sep 2024	10-Q	14 Nov 2024	2024	Q3
Q2 2024	$12,098,000			30 Jun 2024	10-Q	14 Aug 2024	2024	Q2
Q1 2024	$9,977,000			31 Mar 2024	10-Q	08 May 2024	2024	Q1
Q4 2023	$11,624,000			31 Dec 2023	10-K	03 Mar 2025	2024	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.